• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO MEDICAL CORPORATION 8F ANGIO-SEAL EVOLUTION VASCULAR CLOSURE DEVICE, US; DEVICE, HEMOSTASIS, VASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO MEDICAL CORPORATION 8F ANGIO-SEAL EVOLUTION VASCULAR CLOSURE DEVICE, US; DEVICE, HEMOSTASIS, VASCULAR Back to Search Results
Model Number N/A
Medical Device Problem Code Activation, Positioning or Separation Problem (2906)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 12/10/2020
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Implanted date: device was not implanted.Explanted date: device was not explanted.The actual device was not returned for evaluation.The investigation is currently ongoing.A follow up report will be submitted once the investigation is complete.A review of the device history record of the product code/lot# combination was conducted with no findings.
 
Event or Problem Description
The user facility reported that when deploying the 8fr angio-seal evolution after a failed perclose attempt, the device and sheath components would not lock together.When they pulled back, the entire device came out.Manual pressure was held.The patient's condition was stable.The procedure was completed as intended.There was no patient injury, medical/surgical intervention required.The estimated blood loss was less than 250cc.Additional information was received on 14dec2020.The procedure was a left heart catheterization.
 
Additional Manufacturer Narrative
This report is being submitted as follow up no.1 to provide the completed investigation results.The actual device was not returned; therefore, an evaluation of the actual device was unable to be conducted.The complaint cannot be confirmed for pullout since the sample was not available for investigation.Based on the information given, the exact root cause of the event cannot be determined.The device was in a conforming state when released from terumo control.There is no indication that any manufacturing issues may have led to this event.Currently, no action is recommended since this risk evaluation is within the predetermined limits in the fmea.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
8F ANGIO-SEAL EVOLUTION VASCULAR CLOSURE DEVICE, US
Common Device Name
DEVICE, HEMOSTASIS, VASCULAR
Manufacturer (Section D)
TERUMO MEDICAL CORPORATION
265 davidson ave
suite 320
somerset NJ 08873
MDR Report Key11077847
Report Number3013394970-2020-00852
Device Sequence Number13767367
Product Code MGB
UDI-Device Identifier00389701011776
UDI-Public00389701011776
Combination Product (Y/N)N
Initial Reporter StateNE
Initial Reporter CountryUS
PMA/510(K) Number
P930038
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source company representative,health
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 12/28/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date03/21/2021
Device Model NumberN/A
Device Catalogue NumberC610135
Device Lot Number06102537
Was Device Available for Evaluation? No
Initial Date Received by Manufacturer 12/10/2020
Supplement Date Received by Manufacturer01/27/2021
Initial Report FDA Received Date12/28/2020
Supplement Report FDA Received Date01/29/2021
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
PINNACLE 6FR SHEATH 10CM; PINNACLE 6FR SHEATH 10CM
Outcome Attributed to Adverse Event Required Intervention;
Patient Age88 YR
-
-